Global Exosomes Market: 2024-2031
Report Overview Global Exosomes Market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.7 billion by 2031, growing at a CAGR of 15.6% during the forecast period 2024-2031 Exosomes,... もっと見る
SummaryReport OverviewGlobal Exosomes Market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.7 billion by 2031, growing at a CAGR of 15.6% during the forecast period 2024-2031 Exosomes, small vesicles 30 to 200 nm, are secreted from cells to mediate signaling in the tumor necrosis factor (TNF)-induced mesenchymal stem cells (TME). Oncogenic EGFR can be shed from cells and interact with other TME cells. Exosomes from gastric cancer cells can regulate the liver microenvironment and promote liver metastasis. EGFR-containing exosomes can be captured by endothelial cells, eliciting EGFR-dependent responses and VEGF secretion. Exosomes from EGFR-mutated NSCLC can promote CD8+ T cell apoptosis, potentially affecting immunotherapy efficacy. Market Dynamics: Drivers & Restraints Rise in the prevalence of cancers. The increasing prevalence of cancer has led to a growing demand for innovative therapies. Exosome-based technologies, such as liquid biopsy, are being used to analyze biomarkers in bodily fluids like blood, urine, or saliva. Exosomes, as stable carriers of molecular information, are ideal candidates for liquid biopsy approaches. Researchers are exploring the use of exosomal biomarkers for disease progression, treatment response, and detecting minimal residual disease. For instance, according to the National Center for Health Statistics, In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. Technical complexity of exosome isolation and technological limitations Exosomes, characterized by their size, composition, and cargo, present a technical challenge in isolating them with high purity and specificity. The absence of standardized methods can lead to variability in experimental outcomes and hinder comparability between studies. The isolation process is technically demanding due to the presence of other extracellular vesicles and contaminants. Obtaining pure and high-yield exosome isolation requires sophisticated techniques, which can affect the quality and consistency of the obtained samples. Market Segment Analysis The global exosomes market is segmented based on product type, application, end-user, and region. The kits and reagents from the product type segment accounted for approximately 47.3% of the exosomes market share The kits and reagents from the product type segment accounted for approximately 47.3%. Kits and reagents are essential tools in exosome research and clinical applications. They facilitate the isolation, detection, and analysis of exosomes from biological samples like blood, urine, and cell culture media. These tools ensure high yield and purity while preserving biological integrity. Kits simplify the isolating process, making it accessible to those with limited technical expertise. Reagents, like antibodies and dyes, label and detect exosomal surface markers, enabling the characterization of exosome cargo. This is crucial for diagnostics, particularly in identifying biomarkers for diseases like cancer, neurodegenerative disorders, and cardiovascular conditions. For instance, in July 2023, Shimadzu Corporation developed Exorapid-qIC, an immunochromatography kit for extracellular vesicles (CD9) launched by Dai Nippon Toryo Co., Ltd., it is the world's first kit targeting exosomes. The kit includes gold nanoplate-labeled antibodies, immunochromatography test paper, and rinse solution. Shimadzu is responsible for detecting EV types and optimizing the detection system. Market Geographical Analysis North America is estimated to hold about 38.4% of the total market share throughout the forecast period North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to the rising government funding for the detection of new biomarkers and the increasing incidence of chronic conditions, such as cardiovascular diseases and cancer. In addition, growing research & development activities for the development of novel drugs, diagnostic methods, and treatment options are anticipated to drive the segment growth. For instance, in July 2024, Aruna Bio, a leader in neural exosome-based therapeutics for neurodegenerative conditions, received a US Patent No. 11,993,787 for its lead program, AB126, an exosome derived from neural stem cells. The patent, which extends protection covering the composition of matter for AB126 and products for gene therapy using AB16, is expected to be granted by 2038. Market Segmentation By Product Type Kits and Reagents Instruments Others By Application Cancer Applications Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer Other Non-Cancer Applications By End User Diagnostics Hospitals & Clinical Testing Laboratories Others By Region North America U.S. Canada Mexico Europe Germany UK France Italy Spain Rest of Europe South America Brazil Argentina Rest of South America Asia-Pacific China India Japan South Korea Rest of Asia-Pacific Middle East and Africa Market Competitive Landscape The major global players in the market include STARTEK Health, Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen, Thermo Fisher Scientific Inc. among others. Key Developments In January 2024, EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, launched ExoXpert, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers an MSC-based exosome manufacturing platform used in European clinical trials and is a wholly-owned subsidiary of EXO Biologics. Why Purchase the Report? To visualize the global exosomes market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players. Identify commercial opportunities by analyzing trends and co-development. Excel data sheet with numerous data points of the exosomes market level with all segments. PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study. Product mapping available as excel consisting of key products of all the major players. The global exosomes market report would provide approximately 64 tables, 61 figures, and 186 pages. Target Audience 2024 Manufacturers/ Buyers Industry Investors/Investment Bankers Research Professionals Emerging Companies Table of Contents1. Methodology and Scope1.1. Research Methodology 1.2. Research Objective and Scope of the Report 2. Definition and Overview 3. Executive Summary 3.1. Snippet by Product Type 3.2. Snippet by Application 3.3. Snippet by End User 3.4. Snippet by Region 4. Dynamics 4.1. Impacting Factors 4.1.1. Drivers 4.1.1.1. Rise in the prevalence of cancer 4.1.1.2. Increasing focus on personalized medicine 4.1.2. Restraints 4.1.2.1. Technical complexity of exosome isolation and technological limitations 4.1.3. Opportunity 4.1.4. Impact Analysis 5. Industry Analysis 5.1. Porter's Five Force Analysis 5.2. Supply Chain Analysis 5.3. Pricing Analysis 5.4. Regulatory Analysis 5.5. Patent Analysis 5.6. PESTLE Analysis 5.7. SWOT Analysis 5.8. DMI Opinion 6. By Product Type 6.1. Introduction 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 6.1.2. Market Attractiveness Index, By Product Type 6.2. Kits and Reagents* 6.2.1. Introduction 6.3. Instruments 6.4. Others 7. By Application 7.1. Introduction 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 7.2. Market Attractiveness Index, By Application 7.3. Cancer Applications* 7.3.1. Introduction 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%) 7.4. Non-Cancer Applications 8. By End User 8.1. Introduction 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User 8.1.2. Market Attractiveness Index, By End User 8.2. Diagnostics* 8.2.1. Introduction 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%) 8.3. Hospitals & Clinical Testing Laboratories 8.4. Others 9. By Region 9.1. Introduction 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region 9.1.2. Market Attractiveness Index, By Region 9.2. North America 9.2.1. Introduction 9.2.2. Key Region-Specific Dynamics 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 9.2.6.1. U.S. 9.2.6.2. Canada 9.2.6.3. Mexico 9.3. Europe 9.3.1. Introduction 9.3.2. Key Region-Specific Dynamics 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 9.3.6.1. Germany 9.3.6.2. UK 9.3.6.3. France 9.3.6.4. Italy 9.3.6.5. Spain 9.3.6.6. Rest of Europe 9.4. South America 9.4.1. Introduction 9.4.2. Key Region-Specific Dynamics 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 9.4.6.1. Brazil 9.4.6.2. Argentina 9.4.6.3. Rest of South America 9.5. Asia-Pacific 9.5.1. Introduction 9.5.2. Key Region-Specific Dynamics 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 9.5.6.1. China 9.5.6.2. India 9.5.6.3. Japan 9.5.6.4. South Korea 9.5.6.5. Rest of Asia-Pacific 9.6. Middle East and Africa 9.6.1. Introduction 9.6.2. Key Region-Specific Dynamics 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User 10. Competitive Landscape 10.1. Competitive Scenario 10.2. Market Positioning/Share Analysis 10.3. Mergers and Acquisitions Analysis 11. Company Profiles 11.1. STARTEK Health* 11.1.1. Company Overview 11.1.2. Product Portfolio and Description 11.1.3. Financial Overview 11.1.4. Key Developments 11.2. Diagenode Inc 11.3. Fujifilm Holdings Corporation 11.4. Hitachi Chemical Diagnostics Inc 11.5. Lonza 11.6. MBL International 11.7. Miltenyi Biotec 11.8. Novus Biologicals 11.9. Qiagen 11.10. Thermo Fisher Scientific Inc (*LIST NOT EXHAUSTIVE) 12. Appendix 12.1. About Us and Services 12.2. Contact Us
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
DataM Intelligence社の医薬分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問DataM Intelligence社はどのような調査会社ですか?DataM Intelligenceは世界および主要地域の広範な市場に関する調査レポートを出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |